You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Fingolimod,cytokine,chemokine,RRMS

Showing 1 - 25 of 2,028
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Natural Killer Cells in Multiple Sclerosis Patients Treated With

Terminated
  • Relapsing-Remitting Multiple Sclerosis
    • Berlin, Germany
      Charité Universitätsmedizin Berlin
    Jul 28, 2021

    Relapsing Remitting Multiple Sclerosis Trial in Mecidiyekoy, Uskudar, Istanbul (Fingolimod 0.5 mg)

    Completed
    Has Results
    • Relapsing Remitting Multiple Sclerosis
    • Fingolimod 0.5 mg
    • Mecidiyekoy, Istanbul, Turkey
    • +2 more
    Sep 3, 2019

    Neurodegeneration in Multiple Sclerosis -Preclinical Study

    Not yet recruiting
    • Relapsing-Remitting Multiple Sclerosis (RRMS)
    • +2 more
    • Peripheral blood withdrawal
    • Pozzilli, Isernia, Italy
    • +2 more
    Feb 15, 2022

    Deficient T Regulatory Cell Function in Relapsing Remitting

    Recruiting
    • Relapse Remitting Multiple Sclerosis
      • Philadelphia, Pennsylvania
        Thomas Jefferson University
      Jun 13, 2022

      Mechanistic Studies of Teriflunomide in RRMS

      Active, not recruiting
      • Relapsing Remitting Multiple Sclerosis
      • Ann Arbor, Michigan
        University of Michigan
      Jul 27, 2022

      Chemo-Induced Peripheral Neuropathy, Numbness, Pain Trial in Rochester, Columbus (Fingolimod, Fingolimod Hydrochloride,

      Active, not recruiting
      • Chemotherapy-Induced Peripheral Neuropathy
      • +3 more
      • Rochester, Minnesota
      • +1 more
      Jan 17, 2023

      Pulmonary Immune Cell-microbiome Interactions in Healthy Lung

      Recruiting
      • Healthy
      • Bronhcoalvelar lavage
      • Hvidovre, Denmark
        Hvidovre Hospital, University of Copenhagen
      Apr 27, 2023

      Intracerebral Hemorrhage Trial (Fingolimod)

      Not yet recruiting
      • Intracerebral Hemorrhage
      • (no location specified)
      Oct 17, 2023

      Brain Abnormalities in Multiple Sclerosis.

      Recruiting
      • Multiple Sclerosis
      • Dimethyl Fumarate 240 MG [Tecfidera]
      • Messina, Italy
        IRCCS Centro Neurolesi "Bonino-Pulejo"
      Mar 31, 2023

      Multiple Sclerosis Trial in Cairo (Blood sample collection)

      Recruiting
      • Multiple Sclerosis
      • Blood sample collection
      • Cairo, Egypt
        Nasser Institute for Research and Treatment
      Feb 21, 2023

      Breast Carcinoma Trial in Rochester, Columbus, Richmond (Fingolimod, Fingolimod Hydrochloride, Questionnaire Administration)

      Active, not recruiting
      • Breast Carcinoma
      • Rochester, Minnesota
      • +2 more
      Jul 6, 2022

      Multiple Sclerosis (MS) Trial in Worldwide (Fingolimod, Ofatumumab, Siponimod)

      Recruiting
      • Multiple Sclerosis (MS)
      • Little Rock, Arkansas
      • +55 more
      Jan 13, 2023

      Multiple Sclerosis Trial in Worldwide (Interferon beta-1a, Fingolimod, Placebo capsule)

      Recruiting
      Has Results
      • Multiple Sclerosis
      • Interferon beta-1a
      • +3 more
      • Birmingham, Alabama
      • +106 more
      Jan 13, 2023

      Fatigue, Functionality, Multiple Sclerosis Trial in Denizli (Nine-Hole Peg Test (NHPT))

      Completed
      • Fatigue
      • +3 more
      • Nine-Hole Peg Test (NHPT)
      • Denizli, Turkey
        Pamukkale Unıversity
      May 25, 2023

      Relapsing Multiple Sclerosis Trial in Worldwide (Ofatumumab)

      Recruiting
      • Relapsing Multiple Sclerosis
      • Ofatumumab
      • Cullman, Alabama
      • +165 more
      Jan 13, 2023

      Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection Trial in Houston (Fingolimod, Placebo)

      Enrolling by invitation
      • Interstitial Fibrosis
      • +6 more
      • Houston, Texas
        Houston Methodist Research Institute
      Jan 23, 2023

      Bafiertam Treatment In Routine Clinical Practice

      Enrolling by invitation
      • Relapsing Remitting Multiple Sclerosis
      • Monomethyl Fumarate
      • West Hollywood, California
      • +1 more
      Aug 3, 2023

      Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic Trial in Winston-Salem (Fingolimod 0.5 mg, Placebo, Standard of

      Recruiting
      • Intracerebral Hemorrhage
      • +4 more
      • Fingolimod 0.5 mg
      • +2 more
      • Winston-Salem, North Carolina
        Wake Forest University Health Sciences
      Nov 28, 2022

      Multiple Sclerosis, Neurogenic Bladder Trial in Lubbock (vaginal estriol)

      Completed
      Has Results
      • Multiple Sclerosis
      • Neurogenic Bladder
      • vaginal estriol
      • Lubbock, Texas
        Texas Tech University Health Sciences Center
      Aug 25, 2022

      A Post-Authorization, Long-term Study of Ozanimod Real-world

      Active, not recruiting
      • Multiple Sclerosis, Relapsing-Remitting
        • Bethesda, Maryland
          Evidera
        Oct 31, 2022

        Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial in

        Suspended
        • Anatomic Stage 0 Breast Cancer AJCC v8
        • +18 more
        • Buffalo, New York
          Roswell Park Cancer Institute
        Oct 4, 2022

        Relapsing-Remitting Multiple Sclerosis Trial in Worldwide (Ocrelizumab, Ocrelizumab Placebo, Fingolimod)

        Recruiting
        • Relapsing-Remitting Multiple Sclerosis
        • La Jolla, California
        • +66 more
        Jan 27, 2023

        Multiple Sclerosis Trial in Amsterdam (MS Sherpa)

        Recruiting
        • Multiple Sclerosis
        • MS Sherpa
        • Amsterdam, Netherlands
          Amsterdam UMC, locatie VUmc
        Nov 4, 2023

        Multiple Sclerosis Trial in Denizli (Expanded Disability Status Scale, pulmonary function test, International Physical Activity

        Completed
        • Multiple Sclerosis
        • Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
        • Denizli, Turkey
          Pamukkale University
        Jan 24, 2023

        Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative Trial in Buffalo (procedure, drug, biological)

        Active, not recruiting
        • Triple -Negative Breast Cancer
        • +4 more
        • Biopsy
        • +5 more
        • Buffalo, New York
          Roswell Park Cancer Institute
        Aug 1, 2022